Drug intelligence / Profile preview

Atropan-D

Development stage: Unknown
Lead developer: Atro Pharma
Modality: Small Molecules
Administration: Oral

Overview

Atropan-D is an oral sustained-release combination capsule developed by Atro Pharma for the treatment of gastrointestinal disorders. It contains 40mg of pantoprazole, a proton pump inhibitor that reduces gastric acid secretion by inhibiting the H+/K+-ATPase enzyme, and 30mg of domperidone, a dopamine D2 receptor antagonist that acts as a prokinetic agent to enhance gastric emptying and provide antiemetic effects. The drug is indicated for gastroesophageal reflux disease (GERD), erosive esophagitis, gastritis, and peptic ulcers, particularly when associated with symptoms like nausea, bloating, and heartburn. It is currently approved and marketed in India.

Brand names: Atropan-DAtropan D
Other names: domperidone + pantoprazole

Targets

ATP4A (Potassium–transporting ATPase alpha chain 1)

Beyond the preview

Go deeper on Atropan-D.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Atropan-D.

Explore the full profile